Videos

Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.

Julia Han Noll, PhD, University of Pennsylvania, Philadelphia, Pennsylvania, presented mechanistic data identifying a distinct spectrum of delayed toxicities associated with BCMA-directed CAR T-cell therapy at the 2025 ASH Annual Meeting &...

Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.

Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.

Benjamin Kann, MD, discusses results from a large retrospective study evaluating an automated AI-based imaging platform to predict extranodal extension in patients with oropharyngeal carcinoma using pretreatment CT scans.

Farshid Dayyani, MD, PhD, discusses results from a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular carcinoma, including...

Farshid Dayyani, MD, PhD, discusses the background and methods of a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular...

Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.

Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 study evaluating TATE combined with nivolumab in patients with advanced hepatocellular carcinoma who progressed on prior immunotherapy.

Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.